Rising Risk of Heart Disease

Featuring Dr Rajay Narain MRCP, Chairman, Global Health Alliance, UK Hon. Consultant Cardiologist, St. George's University Hospital, London, in conversation with Harbinder Narula, CEO, BW Healthcareworld & BW Wellbeingworld.

Excited to share my latest article on the growing burden of Cardio-Renal-Metabolic diseases and the critical role of early detection through urine albumin-creatinine ratio (uACR) testing published by Abbott for Global HCP reach.
#CardioRenalMetabolic

📢 Our Chairman, Dr. Rajay Narain, will be speaking at BUCA-KCL-VECTOR Conference 2025 on Cardio-Renal Metabolic Changes in the New World at King’s College, London.
.
.
.
#BUCA #BUCA2025 #KCL #Vector #Cardiology #HeartHealth #MedicalConference #FutureDoctors #MedTwitter

Join us for the Masterclass in Lipid Management on March 13, 2025, from 6:30 PM to 7:30 PM GMT! Gain insights from leading experts on the latest guidelines.
✅ Earn 2 CME Points
📍 Expert Speakers: Dr. Rajay Narain & Dr. Mimi Chen
🔗 Register now:tinyurl.com/5n7reces

Empowering Health & Well -Being Globally 🌍

Our Expertise :
- Medical Affairs
- Medical Education
- Medical Conferences and Events
- Healthcare Skilling Courses

#GlobalHealthAlliance #HealthcareTraining #MedicalEducation #EmergencyCare #MedicalSkills #HealthcareForAll

Today, we unite in the fight against cancer. Let’s raise our voices, spread awareness, and offer hope to those battling this disease. Every step forward is a step closer to a cure. #WorldCancerDay #CancerAwareness #FightCancer #HopeInTheFight #TogetherWeCan #SupportTheWarriors

Coffee drinking timing and mortality in US adults

Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.

#CardioSky

academic.oup.com/eurheartj/ad...

#HappyNewYear

#MerryChristmas

bbc.co.uk/news/articles/…

12 Years to roll out this important drug is ‘too long ‘, many high risk patients will miss out #CardioSkyk#MedSkyk#CardioMetabolici#Obesityty

SUMMIT phase 3 study showing benefit of Tirzepatide in adults with HFpEF and obesity, 38% reduction of HF hospitalization, diuretic intensification, or CV death. #CardioSky #MedEd #HeartFailure #Obesity
clinicaltrialresults.org/wp-content/upl…

Excellent lowering of Lp(a) with oral muvalaplin (apo(a)-apoB disruptor) among those with Lp(a)>175 nmol/L + ASCVD, T2D, or FH. #CardioSky #MedSky #GlobalHealth #Lipids #CardioMetabolic